Detail of "57149-07-2"

MSDS Download
CAS Number:
57149-07-2
Name:
1-Piperazineethanol,4-(2-methoxyphenyl)-a-[(1-naphthalenyloxy)methyl]-
Superlist Name:
Naftopidil
Molecular Structure:
Formula:
C₂₄H₂₈N₂O₃
Molecular Weight:
392.49
Synonyms:
3-[4-(2-Methoxyphenyl)piperazinyl]-1-naphthyloxypropan-2-ol;Avishot;Flivas;KT 611;Naftopidil;Naftopil;
Density:
1.184 g/cm³
Melting Point:
127 °C
Boiling Point:
602.8 °C at 760 mmHg
Flash Point:
318.3 °C
Solubility:
methanol: >10 mg/mL particular

Famous Chemical Enterprises

Livzon
Total
Shell
Dupont
Exxonmobil
Akzonobel
Basf
Bayer
BP

Other Products

Supplier Location
Supplier Location
- China (Mainland)(23)
- Hong Kong(1)
- India(1)
- Italy(1)
- Japan(1)
- United States(1)
Business Type
Business Type
- Lab/Research institutions(3)
- Manufacturers(3)
- Trading Company(20)
Certificates
Certificates
- Production License(2)
- ISO(1)

Please post your buying leads>>

Display：

Manufacturer
Enterprise Authentication
Suppiers of more reward points first
New supplier

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Reference

Single-blind, randomized controlled study of the clinical and urodynamic effects of an a-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia: Single-blind, randomized controlled study of the clinical and urodynamic effects of an a-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. Yamanishi, Tomonori; Yasuda, Kosaku; Kamai, Takao; Tsujii, Toshihiko; Sakakibara, Ryuji; Uchiyama, Tomoyuki; Yoshida, Ken-Ichiro (Department of Urology, Dokkyo University, Tochigi, Japan). International Journal of Urology, 11(7), 501-509 (English) 2004 Blackwell Publishing Asia Pty Ltd. CODEN: IJURF3. ISSN: 0919-8172. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The aim of our study was to examine the efficacy of naftopidil in terms of the international prostate symptom score (IPSS) and urodynamic parameters in the treatment of benign prostatic hyperplasia (BPH). Eviprostat was used as a control to study the efficacy of naftopidil. Methods: Forty-nine patients with BPH (mean age 67.9 ± 7.8 yr) were involved in the study. Patients were randomly assigned either to the naftopidil group, which was treated with the a-blocker naftopidil (50-75 mg daily, 36 patients), or the eviprostat group, which was treated with phytotherapy (six tablets of eviprostat daily, 13 patients). The mean total IPSS, the total storage and voiding symptom scores, and the quality of life score decreased significantly (P < 0.0001 for each variable) in the naftopidil group, but not in the eviprostat group. In the naftopidil group, analyses showed significant increases in av. and max. flow rate and bladder capacity at first desire to void (P < 0.001, P = 0.001 and P = 0.024, resp.), and significant decreases in the postvoid residual, the percent of residual and the Abrams-Griffiths no. (P = 0.009, P = 0.008 and P = 0.042, resp.). However, in the eviprostat group, no significant changes were noted in terms of these symptomatic and urodynamic parameters. In the pressure/flow study, an improvement in the International Continence Society nomogram grade was noted in 29% of the naftopidil group, but in only 16% of the eviprostat group. Among the 14 patients in the naftopidil group, detrusor overactivity disappeared in 21% and cystometric capacity increased in 36%, but no improvement in detrusor overactivity was noted in the eviprostat group. 59738-67-9 and 57149-07-2 are just another two chemicals used in this study. Naftopidil appears to have been effective in this short-term treatment of BPH. .

Metabolic fate of the novel antihypertensive drug naftopidil: Metabolic fate of the novel antihypertensive drug naftopidil. Niebch, G.; Locher, M.; Peter, G.; Borbe, H. O. (Dep. Biochem., Asta Pharma A.-G., Frankfurt/Main W-6000/1, Germany).There are some reagents with their cas registry numbers 127931-16-2 and 57149-07-2 are used in this study. Arzneim.-Forsch., 41(10), 1027-32 (English) 1991. CODEN: ARZNAD. ISSN: 0004-4172. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The metab. of [14C]naftopidil and the pharmacodynamic actions of its metabolites were investigated. The metabolic pathways in the rat, dog, mouse, and man were qual. similar, with preference for hydroxylation of the Ph or naphthyl moiety of naftopidil. Cleavage of the parent compd. and prodn. of the propylene glycol metabolite was important esp. in the rat and man. In all species investigated, the demethylation of naftopidil occurred to a minor extent. O-Desmethylnaftopidil, (phenyl)hydroxynaftopidil, and (naphthyl)hydroxy naftopidil had similar affinities for the brain a1-adrenoceptors as the parent compd. The naftopidil metabolites, like the parent compds., showed no a2 or b-adrenoceptor affinity. .

Detail of "57149-07-2"

1-Piperazineethanol,4-(2-methoxyphenyl)-a-[(1-naphthalenyloxy)methyl]-

Famous Chemical Enterprises

Related products

Other Products

Supplier Location

Business Type

Certificates

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

CAS No.57149-07-2 Naftopidil

Reference